Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
Plummer, Ruth; Vidal, Laura; Griffin, Melanie; Lesley, Mark; de Bono, Johann; Coulthard, Sally; Sludden, Julieann; Siu, Lillian L; Chen, Eric X; Oza, Amit M; Reid, Gregory K; McLeod, A Robert; Besterman, Jeffrey M; Lee, Chooi; Judson, Ian; Calvert, Hilary; Boddy, Alan V.
Clin Cancer Res
; 15(9): 3177-83, 2009 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-19383817
Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications.
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
DNA Methyltransferase Inhibitors: Development and Applications.
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy.
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Label-free electrochemical detection of human methyltransferase from tumors.
Genome-wide DNA methylation profiles in precancerous conditions and cancers.
Expression pattern of DNA-methyltransferases and its health implication (short review).
Metylacja cytozyny w DNA i jej znaczenie w terapii przeciwnowotworowej.
A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.